ArticleFrontiers in pharmacology2024
Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05789342 (A Four-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-drug Interactions), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Four-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-drug Interactions (DDIs) Between GP681 and Rosuvastatin/Digoxin/Itraconazole/Oseltamivir in Chinese Healthy Volunteers
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Economic evaluation of antibody-drug conjugates (ADCs) in patients with breast cancer: systematic review.European journal of clinical pharmacology · 2025Pooled it
- Machine learning for discovering anticancer compounds from plants and elucidating their mechanisms.Journal of computer-aided molecular design · 2026Review
- Homocysteine-induced bone formation dysfunction reversed by icariin via the AKT/FOXO1 signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Macrophage programming in systemic sclerosis: Niches, networks, and translational horizons.Seminars in immunopathology · 2026Review
- Unraveling the neuroprotective and anti-seizure potential of Calendula officinalis L. extracts in PTZ-induced experimental epilepsy in rats.Journal of molecular histology · 2026Article
- Untangling neuropathic pain: pathophysiological insights and future directions for targeted therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Ligustrazine attenuates high-fat diet-induced neurobehavioral deficits and hepatic dysfunction via modulation of the HO-1/Nrf-2/SIRT-1/PPAR-α axis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Dynamic ecosystems of tumor drug resistance mechanisms: from molecular heterogeneity to systemic interventions.Apoptosis : an international journal on programmed cell death · 2026Review
- Alpha-pinene modulates hippocampal MAPKs/c-Fos pathways during morphine dependence and withdrawal in rats.Psychopharmacology · 2026Article
- Natural simple coumarins and their interaction with AKR1C3: implications for overcoming chemoradioresistance in gastrointestinal carcinomas.Medical oncology (Northwood, London, England) · 2026Article
- Integrative Analysis of Trace Elements, Oxidative Stress, and Psychological Distress in Epilepsy: Biochemical Profiling and In Silico Docking Insights.Neurochemical research · 2026Article
- Pioglitazone Mitigates Arsenic-Induced Cardiotoxicity via Lipid Metabolism: Network Pharmacology and Molecular Docking Approach.Cardiovascular toxicology · 2026Article
- A scoping review of influenza RdRp-targeting inhibitors: mechanisms, clinical translation, and emerging challenges.Frontiers in microbiology · 2026Review
- Mass balance, excretion, and pharmacokinetics of a single oral dose of [Frontiers in pharmacology · 2026Article
- Orchestrating immunopathology: the spectrum of programmed cell death pathways co-opted by influenza a virus in pulmonary immunity.Frontiers in immunology · 2026Review
- Calcineurin Inhibitors: Current Role, Toxicity Management, and Future Frontiers in Immunosuppression.Molecular neurobiology · 2025Review
- Physiologically based pharmacokinetic (PBPK) modeling of drug-drug interactions between suraxavir marboxil and CYP3A4 inhibitors: Quantitative prediction of pharmacokinetic effects on active metabolite GP1707D07.Pharmaceutical science advances · 2025Article
- Lactiplantibacillus plantarum MTCC 25433 and Quercetin Blend Ameliorate Benzo[a]pyrene-Induced Gut Dysregulation in a Murine Model.Current microbiology · 2025Article
- Exploring the potential of bacterial-derived EVs for targeted enzyme replacement therapy: mechanisms, applications, and future directions.Archives of microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Suraxavir Marboxil (GP681) is a prodrug metabolized to GP1707D07, which inhibits influenza viral replication by targeting cap-dependent endonuclease through a single oral dose. This study assesses the in vivo drug-drug interaction (DDI) potential between GP681 (including its major metabolite GP1707D07, a substrate of CYP3A4) and itraconazole in healthy Chinese subjects, along with the safety profiles during co-administration. Additionally, it evaluates the impact of CYP1A2, CYP2C19, and CYP3A4 gene polymorphisms on GP1707D07 metabolism. Methods: The study enrolled twelve healthy adult subjects to receive the treatments consisting of GP681 monotherapy and GP681-itraconazole co-administration in a fixed-sequence. Single nucleotide polymorphisms (SNPs) in CYP gene loci were also analyzed. Results: Co-administration of itraconazole increased the GP1707D07 AUC0- Discussion: The pharmacokinetic changes of GP1707D07 during itraconazole co-administration are insufficient to warrant clinical action. Random forest algorithm enhances the understanding of pharmacogenetic variants involved in GP1707D07 metabolism and may serve as a potent tool for assessing gene polymorphism data in small clinical samples. Clinical Trial Registration: clinicaltrials.gov, identifier NCT05789342.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.